River Birch delivers integrated pharmaceutical consulting, healthcare market strategy, and investment advisory for biotech, specialty pharma, and enterprise health systems.
From regulatory strategy to commercial launch — we cover the full pharmaceutical value chain with domain-specific expertise and a results-first approach.
End-to-end regulatory advisory for IND, NDA, BLA, and 510(k) filings. We navigate FDA, EMA, and global regulatory frameworks to accelerate your path to market while minimizing risk.
Pharma-specialized deal structuring, due diligence, and valuation services for acquisitions, licensing, and biotech investments.
Portfolio prioritization, go/no-go decision frameworks, and asset triage to maximize R&D ROI across your drug development pipeline.
HEOR modeling, payer engagement strategies, and reimbursement pathway design to ensure successful formulary placement.
Go-to-market planning, KOL engagement, and physician outreach design for specialty pharmaceutical product launches.
Investor narrative development, roadshow preparation, and scientific communication for biotech companies pursuing public or private capital.
We combine deep therapeutic area expertise with a rigorous, data-driven methodology to deliver outcomes — not just advice.
We begin with a thorough clinical, competitive, and regulatory assessment — ensuring every engagement is grounded in evidence, not assumptions.
We translate findings into a prioritized strategic roadmap — with defined milestones, risk-adjusted scenarios, and capital allocation frameworks.
We orchestrate alignment across regulators, payers, clinicians, and investors — building the coalition required for sustainable success.
We stay embedded through implementation — adjusting tactics in real time as clinical, regulatory, and market signals evolve.
Rare Disease assets continue to outperform industry benchmarks, with 92% progressing past Phase II — driven by FDA Breakthrough Therapy designation strategy.
Every engagement is measured against real business outcomes — not deliverables. Here's what our clients achieve.
Our team brings decades of experience from top-tier pharma, investment banking, regulatory agencies, and clinical research.
Former SVP at a Big Pharma, Richard brings 22 years of pharmaceutical strategy, global regulatory experience, and biotech investment expertise to every engagement.
Former FDA reviewer turned industry strategist. Sarah has guided 20+ NDA and BLA submissions through FDA review cycles, with a 94% approval track record.
Academic physician and clinical trial architect with expertise in Phase II/III design, adaptive trial methodology, and endpoints for rare and orphan diseases.
Formerly at Goldman Sachs Healthcare Investment Banking. Janet leads all deal structuring, licensing negotiations, and investor relations across the portfolio.
Payer strategy specialist with 14 years of HEOR modeling, value dossier development, and reimbursement pathway experience across specialty and biologics.
Commercial launch architect who has built go-to-market playbooks for 12 specialty launches across oncology, immunology, and rare metabolic disease.
How recent guidances on complex drug-device combinations and 505(b)(2) pathways are reshaping generic entry strategy for specialty pharma companies navigating the post-GDUFA III environment.
New patterns in pharma M&A premiums and how to position assets for maximum deal value.
ICER assessments, outcomes-based contracting, and the new coverage framework reshaping CAR-T and gene therapy reimbursement.
A decision framework for Phase II sponsors facing enrollment challenges or emerging competitive data.
New data on first-year uptake curves, prescriber access, and payer coverage timelines across 24 specialty launches.
Whether you're navigating a complex regulatory pathway, preparing a commercial launch, or structuring a strategic deal — we have the expertise to move you forward.